VRCA vs DERM vs SKIN vs PRGO vs MCK

For growth investors, Verrica Pharmaceuticals Inc.

(VRCA) is the stronger pick with 370. 2% revenue growth year-over-year, versus -29. 1% for Journey Medical Corporation (DERM). McKesson Corporation (MCK) offers the better valuation at 29. 2x trailing P/E (19. 3x forward), making it the more compelling value choice. Analysts rate Verrica Pharmaceuticals Inc. (VRCA) a "Buy" — based on 10 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

On forward P/E, Perrigo Company plc is actually cheaper at 5.

6x — notably different from the trailing picture, reflecting expected earnings growth.

Over the past 5 years, McKesson Corporation (MCK) delivered a total return of +286.

9%, compared to -92. 9% for The Beauty Health Company (SKIN). Over 10 years, the gap is even starker: MCK returned +348. 1% versus VRCA's -95. 3%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), McKesson Corporation (MCK) is the lower-risk stock at 0.

04β versus Verrica Pharmaceuticals Inc. 's 2. 19β — meaning VRCA is approximately 4977% more volatile than MCK relative to the S&P 500. On balance sheet safety, Verrica Pharmaceuticals Inc. (VRCA) carries a lower debt/equity ratio of 7% versus 6% for The Beauty Health Company — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), Verrica Pharmaceuticals Inc.

(VRCA) is pulling ahead at 370. 2% versus -29. 1% for Journey Medical Corporation (DERM). On earnings-per-share growth, the picture is similar: Verrica Pharmaceuticals Inc. grew EPS 88. 6% year-over-year, compared to -723. 2% for Perrigo Company plc. Over a 3-year CAGR, VRCA leads at 57. 9% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

McKesson Corporation (MCK) is the more profitable company, earning 0.

9% net margin versus -50. 3% for Verrica Pharmaceuticals Inc. — meaning it keeps 0. 9% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: PRGO leads at 8. 1% versus -33. 6% for VRCA. At the gross margin level — before operating expenses — VRCA leads at 93. 8%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

On forward earnings alone, Perrigo Company plc (PRGO) trades at 5.

6x forward P/E versus 69. 0x for Journey Medical Corporation — 63. 4x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for DERM: 135. 0% to $11. 75.

In this comparison, PRGO (9.

8% yield), MCK (0. 4% yield) pay a dividend. VRCA, DERM, SKIN do not pay a meaningful dividend and should not be held primarily for income.

For long-horizon retirement investors, McKesson Corporation (MCK) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0.

04), +348. 1% 10Y return). Verrica Pharmaceuticals Inc. (VRCA) carries a higher beta of 2. 19 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (MCK: +348. 1%, VRCA: -95. 3%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

These companies operate in different sectors (VRCA (Healthcare) and DERM (Healthcare) and SKIN (Consumer Defensive) and PRGO (Healthcare) and MCK (Healthcare)), which means they face different economic cycles, regulatory environments, and macro sensitivities — making direct comparison nuanced.

In terms of investment character: VRCA is a small-cap high-growth stock; DERM is a small-cap quality compounder stock; SKIN is a small-cap quality compounder stock; PRGO is a small-cap income-oriented stock; MCK is a mid-cap high-growth stock. PRGO pays a dividend while VRCA, DERM, SKIN, MCK do not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.